Omnicell Showcases Outcomes-Centric Innovation at ASHP Midyear 2023

FORT WORTH, Texas, -- December 4, 2023—Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, will showcase the Company’s outcomes-centric innovation at the American Society of Health-System Pharmacists (ASHP) Midyear 2023 Clinical Meeting and Exhibition, December 4-7, 2023, in Anaheim, California.

Omnicell’s Advanced Services offerings provide varying combinations of robotics, smart devices, software, and expert services that are designed to deliver outcomes in each setting of care where medications are managed. These comprehensive offerings have helped many healthcare facilities reduce manual workflows and waste, improve inventory visibility, and allowed staff to focus on higher value tasks. These Advanced Services offerings are available for point of care, central pharmacy dispensing, IV compounding, inventory optimization, specialty pharmacy, and outpatient digital pharmacy services.

“Surrounding technology with actionable data and expert services has been pivotal in realizing value and ROI for our pharmacy operations,” said Arpit Mehta, PharmD, MPH, MHA, CPEL, Director of Pharmacy at Allegheny General Hospital. “We are able to make critical medication management decisions based on data-driven insights to improve patient safety, enhance efficiency, and ultimately realize significant cost savings.”

Advanced Services Overview

Omnicell’s full suite of Advanced Services offerings are designed to help healthcare pharmacies across the continuum of care to move closer to achieving the Autonomous Pharmacy, an industry-defined vision to replace manual, error-prone activities with automated processes that are designed to be safer and more efficient. These include:

“As pharmacy technology becomes more sophisticated and enhanced by machine learning and AI, we believe health systems need the resources that will allow them to realize the full potential of their medication management infrastructure to enhance outcomes,” said Randall Lipps, chairman, president, chief executive officer and founder of Omnicell. “Our Advanced Services offerings are designed to provide leading-edge technology along with the insights and optimization recommendations to help deliver clinical, financial, and operational goals, all supported by certified clinical and pharmacy experts.”

Continuing Education Opportunities

Omnicell will be supporting two educational opportunities during ASHP Midyear. On Tuesday, Dec. 5, Kevin Hansen, PharmD, Director of Pharmacy, 503B Program
Premier Inc., and Austin Price, Pharm D, Pharmacy Coordinator, Technology and Automation, Cone Health will present the continuing education (CE) session A Shortage Crisis: IV Compounding Automation Success Story, highlighting how IV compounding automation helped Cone Health to navigate labor issues and manage drug shortages, and how this leading edge technology may be able to help health systems achieve USP <797> compliance.

Wednesday, Dec. 6, Omnicell is proud to support Leveraging IV Robotics to Optimize Sterile Compounding Practices to Improve Safety, a CE-accredited educational symposium presented by the Institute for Safe Medication Practices.

To learn more about Omnicell’s outcomes-centric innovation, visit Booth #539 during the Midyear meeting or https://outcomes.omnicell.com.

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its Twitter handle www.twitter.com/omnicell, LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “estimate,” “seek,” “predict,” “project,” and variations of these terms and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to the objectives and expected benefits of Omnicell’s products and services, including expectations regarding Omnicell’s Central Pharmacy Dispensing Service (and any implied financial impact with the foregoing). Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (ii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iii) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (iv) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, (vi) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (vii) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) Omnicell’s ability to recruit and retain skilled and motivated personnel, and (x) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

OMCL-G